Veracyte Inc. (VCYT)
Veracyte Inc. (VCYT) Stock Price, Analysis & Data
| Geld | 33.3 |
| Marktkapitalisierung | 3.34 Mrd |
| Umsatz (TTM) | 561.9 Mio |
| Nettogewinn (TTM) | 114.48 Mio |
| Beta | 1.94 |
| EPS (ttm) | 1.4 |
| KGV (TTM) | 29.63 |
| Forward-KGV | 21.29 |
| KBV (TTM) | 2.51 |
| KUV (TTM) | 5.94 |
| Earnings Date | Nov 3, 2026 |
| Brief | 59.52 |
| Volumen | 428,486 |
| Ø Vol. (20D) | 1,334,545 |
| Eröffnung | 41.92 |
| Vortagesschluss | 40.68 |
| Tagesspanne | 40.09 - 42.46 |
| 52-Wk Range | 28.25 - 60.91 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über VCYT
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nC...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Veracyte 517.14 Mio, ein Anstieg von 16.01% im Vergleich zum Vorjahr (445.76 Mio). Der Gewinn lag bei 66.35 Mio, ein Anstieg von 174.89 %.
FinanzberichteGewinnüberraschung
Analysten erwarten einen Umsatz von ... Upgrade
vor 2 Wochen · Simply Wall St.
Is Veracyte (VCYT) Fully Valued After Raising 2026 Revenue Guidance?Veracyte (VCYT) is back in focus after raising its 2026 revenue guidance to a range of US$590 million to US$596 million, and releasing detailed second quarter and first half earnings results. See our ...
